Sialyl-Tn (STn) Antigen Vaccine Development Service
Professional STn Antigen Vaccine Development That Exceeding Your Expectations
Tumor-associated carbohydrate antigens have emerged as key targets for the development of synthetic anticancer vaccines. CD BioGlyco synthesizes the vaccine by late-stage convergent assembly strategy, using chemically selective click-type chemistry. We apply combining immunology with click chemistry to Vaccine Development with tumor-based glycans to generate a more effective carbohydrate immune response. At CD BioGlyco, we provide a complete strategy for antigen vaccine development including design, synthesis, and immunological evaluation services.
- Design and Synthesis
Our researchers have proven experience in the design and synthesis of Carbohydrate Click-based Sugar-conjugated Vaccines. First, we synthesize a series of multivalent sugar-based macromolecules as cellular epitope carriers. We provide STn-based sugar dendrimer synthesis services, in which GalNAc units are attached to serine hydroxyl groups. During the synthesis process, we provide protection services for specific reactive groups.
We use copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) click chemistry to attach the amino-GalNAc portion to a multivalent oxaldehyde-functionalized scaffold. Moreover, we provide mutual analysis services to assess their ability to be recognized by anti-STn antibodies.
- Immunological Evaluation
We immunize the mice to assess the immunocompetence of the synthetic STn vaccine. Serological analyses of mouse blood are performed to assess cellular immunity. Notably, during the immunization process, our researchers pay close attention to the status of mice (e.g., inflammation, systemic reaction, weight loss, or death) to assess the side effects of the vaccine.
We measure the total antibody levels in the serum by enzyme-linked immunosorbent assay (ELISA). We test the ability of antisera to recognize STn in its natural environment. In addition, we also provide a service to analyze the binding of vaccine-induced serum antibodies to cancer cell lines expressing natural antigens.
Publication
Technology: ELISA, High-performance liquid chromatography (HPLC), Electrospray ionization mass spectrometry (ESI-MS), Knockout, Nuclear magnetic resonance (NMR)
Journal: Chembiochem
Published: 2017
IF: 3.461
Results: In this study, we synthesized a salivary Tn cyclic peptide scaffold with a helper T-cell peptide epitope (PADRE) using microbial and click chemistry approaches. The target carbohydrate was produced by recombinant expression and then conjugated to the immunogenic scaffold using CuAAC click chemistry to create an anti-cancer vaccine. The results of multiple analyses showed that the vaccine could be rapidly and efficiently recognized by STn antibodies. The ability of the glycocouple to interact with monoclonal antibodies was also confirmed.
Fig.1 1H NMR spectrum of Neu5Ac-α-2,6-GalNAc-α-propargyl. (Richard, et al., 2017)
Applications of STn Antigen Vaccine
- STn antigen vaccines produce potent and specific humoral and cellular immune responses.
- STn antigen vaccines are a useful candidate target for cancer immunotherapy.
- The STn antigen vaccine offers broad possibilities for further clinical promotion and individualized vaccine therapy.
Advantages of Us
- To circumvent the challenges associated with natural Tn-Ser vaccine candidates, we synthesize STn antigen vaccines by oxime linkage displaying STn analogs.
- The STn vaccine development services we offer have superior synthetic and immunological properties.
- Multifold increased carbohydrate sites in our developed STn vaccine, promoting the need for B cell activation and antibody production.
Frequently Asked Questions
- How to stabilize the removal of the O-acetyl and Fmoc parts of the various deprotection?
To address this issue, we devise an alternative strategy to achieve a modified vaccine structure, in which the internal oxime linkage is replaced by 1,4-triazole. Since this modification involves the "internal" part of the glycosylated structure and not the external B-cell epitope display, the binding capacity of the structure should not be affected.
- Why choose STn antigen to develop vaccines?
STn is overexpressed in a variety of cancers such as ovarian, breast, and colon cancers, but is undetectable in normal healthy tissues. The aberrant expression of STn is closely related to the dysregulation of the O-glycosylation mechanism, mainly the unbalanced expression of Cosmc and STn synthase (ST6GalNAc-I). These unbalanced expressions lead to strong cancer cell aggressive behavior and accelerate tumor growth. Thus, STn is critical for the development of cancer immunotherapies.
CD BioGlyco has a professional synthetic team and analysts to help clients quickly develop antigen vaccines. Meanwhile, our service not only involves the design and synthesis of vaccines but also includes a series of bioactivity assessment services. If you are interested in our service, please feel free to contact us.
References
- Richard, E.; et al. Chemobacterial synthesis of a sialyl-Tn cyclopeptide vaccine candidate. Chembiochem. 2017, 18(17): 1730-1734.
- Pifferi, C.; et al. Chemical synthesis and immunological evaluation of new generation multivalent anticancer vaccines based on a Tn antigen analogue. Chem Sci. 2020, 11(17): 4488-4498.
For research use only. Not intended for any clinical use.
Related Services
